ERSPC
Trial question
What is the role of PSA testing in males for prostate cancer screening?
Study design
Multi-center
Open label
RCT
Population
162243 male patients.
Inclusion criteria: males between the ages of 55 and 69 years.
Key exclusion criteria: diagnosis of prostate cancer.
Interventions
N=72890 prostate cancer screening (PSA screening at an average of once every 4 years).
N=89353 no screening (did not receive PSA screening).
Primary outcome
Death from prostate cancer
0.29%
0.36%
0.4 %
0.3 %
0.2 %
0.1 %
0.0 %
Prostate cancer
screening
No
screening
Significant
decrease ▼
NNT = 1428
Significant decrease in death from prostate cancer (0.29% vs. 0.36%; aRR 0.8, 95% CI 0.65 to 0.98).
Conclusion
In males between the ages of 55 and 69 years, prostate cancer screening was superior to no screening with respect to death from prostate cancer.
Reference
Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8.
Open reference URL